Company Overview and News

3
The Charles Schwab's (SCHW) CEO Walt Bettinger on 2018 Fall Business Update - Transcript

17h seekingalpha
The Charles Schwab Corporation (NYSE:SCHW) 2018 Fall Business Update Conference Call October 19, 2018 11:00 AM ET
83SF BCS OIL SCHW 83SK 47MC

12
Barclays hires technology services banker from Deutsche Bank

23h channelnewsasia
Barclays PLC said on Friday it had hired an investment banker from Deutsche Bank AG, Ed Wehle, to focus on technology services deals based in New York.
LMT BCS DB LDOS 83SF 83SK 9613 47MC C NTDTY CTSH CGBBW

 
Leap Greens Energy appoints Barclays Bank to raise $250 million

2018-10-19 thehindubusinessline
Leap Greens Energy (LGE), an independent power producing company, has appointed Barclays Bank as financial advisors to raise close to $250 million.
83SF BCS OIL 83SK 47MC

6
Leap Green appoints Barclays to help raise $300-400 million

2018-10-19 livemint
Mumbai: Tamil Nadu-based renewable energy company Leap Green Energy Pvt. Ltd has appointed investment bank Barclays Plc to help in raising $300-400 million as it seeks to grow its portfolio, said two people aware of the development. Founded in 2006, Leap Green is promoted by former Formula 1 driver Narain Karthikeyan’s family.
MQBKY BCS IFK 83SF GS GLSSP 83SK MQG 47MC JBK IFX GSC TFG MCQEF GSJ GJS

3
Big Oil's Hired Hands Chase Foreign Boom

2018-10-18 rigzone
(Bloomberg) -- The biggest providers of oilfield services are surfing a wave of international spending on the back of higher prices, but the good news is tempered by an activity slowdown in their own back yard.
BCS BHI 83SF 83SK MS 47MC

 
Is It Time To Buy The 'Metal Of The Future'?

2018-10-15 seekingalpha
Aluminium, known as “the metal of future”, has borne out of the volatility of alumina prices in October.
83SF BCS OIL 83SK 47MC

3
RPT-INSIGHT-With risky bets back in play, stock selloff revives 'Volmageddon' memories

2018-10-15 reuters
NEW YORK, Oct 12 (Reuters) - Months after he lost millions when an esoteric corner of financial markets cratered in February, former Target Corp store manager Seth Golden is betting against volatility again.
SVXY 83SF BCS TGT 83SK FDS NYTAB 47MC

6
Barclays to challenge Goldman in digital-only bank market: FT

2018-10-14 channelnewsasia
Barclays Plc is launching a retail account that will offer U.S. consumers a low-cost, digital-only bank with the backing of a major financial institution, the Financial Times reported on Sunday.
JBK BCS GSC TFG GSJ 83SF GS GLSSP 83SK GJS 47MC

6
Barclays to challenge Goldman in digital-only bank market -FT

2018-10-14 reuters
NEW YORK (Reuters) - Barclays Plc (BARC.L) is launching a retail account that will offer U.S. consumers a low-cost, digital-only bank with the backing of a major financial institution, the Financial Times reported on Sunday.
JBK BCS GSC TFG GSJ 83SF GS GLSSP 83SK GJS 47MC

3
INSIGHT-With risky bets back in play, stock selloff revives 'Volmageddon' memories

2018-10-12 reuters
NEW YORK (Reuters) - Months after he lost millions when an esoteric corner of financial markets cratered in February, former Target Corp store manager Seth Golden is betting against volatility again.
SVXY 83SF BCS TGT 83SK FDS NYTAB 47MC

5
Wall Street Sees Treasuries Yield Curve Flattening Into 2019

2018-10-11 theedgemarkets
(Oct 12): This month’s bond-market slump hasn’t jolted the majority of Wall Street strategists from one core view: that the Treasuries yield curve will keep flattening well into next year.
WFCNP BCS DB BNPQY 83SF 83SK MS 47MC WFC BNPQF BNPZY

8
US trial begins for London forex traders accused of rigging prices

2018-10-11 malaymail
NEW YORK, Oct 11 — A US prosecutor yesterday urged jurors in Manhattan federal court to find three former London-based currency traders guilty of scheming to rig prices, kicking off the latest trial to emerge from a US probe into the multitrillion-dollar foreign exchange market.
BCS BNPQY HSB 83SF 83SK UBS HSBC HBCYF 47MC C BNPQF HCS 0005 BNPZY CGBBW HSEA HSEB ULSGF

2
OIL Gets Additional Support From Hurricane Michael

2018-10-10 seekingalpha
Welcome to my Oil Weekly report. In this brief report, I wish to discuss my views on oil markets and the iPath S&P Oil Total Return Index ETN ( OIL).
83SF BHI BCS OIL 83SK 47MC

13
Big Banks Aim to Show Higher Profits Still Ahead as Rates Rise

2018-10-07 theedgemarkets
But as the biggest U.S. banks report results that analysts estimate will set a new high for profitability this decade, shareholders are wondering: is this as good as gets, or is Jamie Dimon right that banks are entering a golden age.
BCS 83SF UGLD 83SK DSLV CSSLF CGBBW WFCNP DGLD CS 47MC WFC C VIIX VIIZ CSGKF ZIV USLV TVIX XIV

 
Bharti Airtel to refinance 1 billion euro debt

2018-10-05 moneycontrol
Telecom operator Bharti Airtel said it has secured full commitment from leading global banks like Bank of America, Barclays Bank and Citibank to refinance the payment of 1 billion euro notes maturing in December this year.
532454 83SF BNPZY BCS OIL 83SK BNPQY BNPQF BHRQY BHARTIARTL 47MC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...